参芪解毒汤治疗浊瘀内停型慢性肾衰竭的临床研究及对外周血黏附分子的影响

Clinical Observation of"Shenqi Jiedu Decoction"in Treating Chronic Renal Failure of Turbidity and Blood-Stasis Syndrome and Its Effects on Peripheral Blood Adhesion Molecule

目的探讨参芪解毒汤对浊瘀内停型慢性肾衰竭(CRF)的疗效及作用机制。方法将159例CRF患者随机分为治疗组80例(用参芪解毒汤加必需氨基酸和科索亚治疗)及对照组79例(用必需氨基酸加科索亚治疗),两组均治疗8周,观察治疗前后肾功能及外周血黏附分子的变化情况。结果治疗组显效率及总有效率分别为61.25%、92.50%,对照组分别为37.97%、65.82%,治疗组疗效明显优于对照组(P<0.05);治疗组治疗后Scr及Ccr较对照组改善更为明显(P<0.05,P<0.01);治疗组治疗后较对照组血黏附分子CD146、ICAM-1、VCAM-1的表达明显减少(P<0.05,P<0.01)。结论参芪解毒汤对浊瘀内停型CRF有良好的治疗作用,作用机制可能与其能显著减少外周血黏附分子的表达有关。

Objective To investigate the clinical effect and mechanism of “Shenqi Jiedu Decoction” （SQJD） in treating chronic renal failure （CRF）. Methods 159 subjects were divided into two groups randomly： treatment group in which 80 cases were treated with SQJD and essential amino acids and Losartan Potassium and control group in which 79 cases were treated with essential amino acids and Losartan Potassium. The renal function and peripheral blood adhesion molecule were observed. Results The markedly effective rate and total effective rate of treatment group were 61.25% and 92.5% respectively and those of the control group were 37.97% and 65.82% respectively （P〈0.05）; after treatment, SCr and CCr were improved more significantly in treatment group than in control group （P〈O.05, P〈O.O1）, CD146, ICAM-1 and VCAM-1 decreased more significantly in treatment group than in control group （P〈O.05, P〈O.O1）. Conclusion SQJD have a satisfactory therapeutic effect on CRF possibly by reducing peripheral adhesion molecule expression.